1.. Introduction {#s1}
================

Antibodies against β~1~-adrenergic receptors (β~1~AR) are frequently found in the serum of patients with chronic heart failure. Their prevalence is associated with Chagas\' disease,^[@CVS350C1]^ dilated cardiomyopathy (DCM),^[@CVS350C2],[@CVS350C3]^ or ischaemic heart disease,^[@CVS350C3]^ but not cardiomyopathies of other aetiology^[@CVS350C4],[@CVS350C5]^. Epitopes most frequently targeted are located in the second extracellular loop of the human β~1~AR.^[@CVS350C6],[@CVS350C7]^ Human autoantibodies and corresponding antibodies raised in rodents against peptides cross-react with native β~1~ARs.^[@CVS350C3],[@CVS350C5],[@CVS350C8]^ They exert positive ino- and chronotropic effects on cardiomyocytes^[@CVS350C5],[@CVS350C9]^ by a mechanism presumed to involve the modulation of receptor conformation.^[@CVS350C4],[@CVS350C10]^ Immunization of rodents against the second extracellular β~1~AR loop induce left ventricular dilation and dysfunction^[@CVS350C11]--[@CVS350C13]^ among other effects compatible with chronic cardiac dysfunction.^[@CVS350C14]--[@CVS350C16]^ Such effects are reversible upon removal of the antibodies,^[@CVS350C17]^ transferable via serum transfusions,^[@CVS350C12],[@CVS350C16],[@CVS350C18],[@CVS350C19]^ and partially abrogated by β~1~AR antagonists^[@CVS350C20]^ or synthetic mimics of the receptor epitope.^[@CVS350C21]--[@CVS350C23]^ In DCM patients, the prevalence^[@CVS350C3]^ and cAMP-stimulatory efficacy^[@CVS350C24]^ of β~1~AR autoantibodies are correlated to more reduced cardiac function,^[@CVS350C3]^ increased mortality,^[@CVS350C25]^ more severe ventricular arrhythmia,^[@CVS350C26]^ and sudden cardiac death.^[@CVS350C27],[@CVS350C28]^ Therefore, autoimmunity against the second extracellular loop of the β~1~AR is considered a cause or cofactor of chronic left ventricular dysfunction and a potential therapy target.^[@CVS350C17],[@CVS350C21]--[@CVS350C23],[@CVS350C29]--[@CVS350C31]^ Interleucin 6 is suspected to play a key role in β~1~AR-induced autoimmune cardiomyopathy through enhancing antibody production.^[@CVS350C32]^ Mechanisms, however, by which the antibodies modulate receptor function are poorly understood.^[@CVS350C33]^ Normal βAR activation involves a conformational switch enabling G-protein coupling.^[@CVS350C34]^ Since β~1~AR autoantibodies recognize conformational epitopes,^[@CVS350C3]^ they are thought to modulate receptor conformation^[@CVS350C4],[@CVS350C10]^ or influence the stability of transient conformational states induced by true ligands.^[@CVS350C16]^ Here, we investigate whether β~1~AR autoantibodies derived from DCM patients indeed trigger changes in β~1~AR conformation.

2.. Methods {#s2}
===========

2.1. Expression of biofluorescent human β~1~AR in HEK293 cells {#s2a}
--------------------------------------------------------------

The human β~1~AR cDNA was fused to yellow fluorescence protein (YFP) at the C-terminus to provide a fluorescent signal of receptor abundance and localization; cyan fluorescence protein (CFP) was additionally inserted into the third intracellular loop (between Pro292 and Gly304) to constitute a fluorescence resonance energy transfer (FRET)-donor/-acceptor pair reporting the activation-associated conformational switch.^[@CVS350C35]^ These constructs were stably expressed in human embryonic kidney 293 cells (HEK293, DSMZ ACC 305, Braunschweig, Germany) and characterized in the intact cell by binding isotherms and isoproterenol displacement of the βAR antagonist \[^3^H\]-(-)-CGP12,177 (Amersham Biosciences, Freiburg, Germany). The βAR subtype was determined by competition-binding studies with the β~1~-selective adrenergic antagonist CGP20712A and the β~2~-selective adrenergic antagonist ICI118551. Stable expression resulted in 8 ± 0.66 and 4.8 ± 0.89 million β~1~-adrenergic-binding sites/cell for YFP-fused and YFP/CFP-fused β~1~AR, respectively, when compared with 100 ± 20 endogenous β~2~AR (\<0.001%). An appropriate size and localization of the overexpressed β~1~AR was confirmed by YFP-directed immunoblotting and immunofluorescence microscopy, respectively. Further characteristics of the cell model are summarized in [Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1) and [*Table S2*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)*)*.

2.2. Selection and preparation of IgG samples {#s2b}
---------------------------------------------

Ten patients with DCM were randomly selected upon presentation for regular outpatient follow-up. At the time of blood sampling, all patients had received stable oral heart failure medication for \>3 months; active infections, known autoimmune diseases, cancer, chronic alcoholism, or heart failure of known origins were excluded; coronary heart disease and acute myocarditis were excluded by angiography and endo-myocardial biopsy according to Dallas criteria, respectively. Ten healthy volunteers with no symptoms of heart disease and the exclusion of left ventricular dysfunction by echocardiography were selected based on age and gender. Characteristics of patients and controls are summarized in [Supplementary material online, *Table S1*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1). The investigation conforms to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the University Greifswald, Germany. Each patient provided written consent. IgG was isolated from the serum^[@CVS350C36]^ or randomly sampled from commercial preparations used for therapeutic IgG substitution (Privigen and Sandoglobulin; CSL Plasma, Marburg, Germany). Total and subclass IgG concentrations were determined by procedures accredited for clinical diagnosis. Peptide analogues of the first (VWGRWEYGSFFCEL, denominated *Pep 1*) or the second (LMHWWRAESDEARRCYNDPKCCD, denominated *Pep 2*) extracellular loop of the human β~1~AR used for pre-absorption and enzyme-linked immunosorbent assay (ELISA) came from nanoTools, Freiburg, Germany.

2.3. Detection quantification of autoantibodies {#s2c}
-----------------------------------------------

IgG binding to a peptide analogue of the second extracellular β~1~AR loop (Pep 2) was quantified by ELISA following published procedures.^[@CVS350C3]^ IgG-colocalization with the native receptor was determined in HEK293 cells stably expressing YFP-fused β~1~AR. Cells were incubated with IgG (20 min, 37°C), followed by washing, fixation (acetone, 5 min, −20°C), and counterstaining with fluorescent goat anti-human IgG (Dianova, Hamburg, Germany). Colocalization of receptor- and antibody-associated fluorescence was visualized by dual colour fluorescence microscopy (LSM 510 Meta confocal microscope, 63x/1.3 DIC oil immersion objective, Carl Zeiss, Jena, Germany) (*Figure [1](#CVS350F1){ref-type="fig"}A*) and quantified by serial IgG dilution starting with the equivalent of a 1:100 dilution of normal serum (134 mg IgG/L) (*Figure [1](#CVS350F1){ref-type="fig"}B*). The ratio of red (bound IgG) and green (β~1~AR abundance) fluorescence emission intensities (FL~R/G~) in the outer cell membrane was normalized to background FL~R/G~ measured with secondary antibody alone. IgG-β~1~AR colocalization was thus detected/quantified as a FL~R/G~ increase above background with the detection limit delineated by the confidence limit of FL~R/G~ background scatter (*Figure [1](#CVS350F1){ref-type="fig"}C*, horizontal dashed line). Rabbit antibodies against the second extracellular loop of the human β~1~AR^[@CVS350C4],[@CVS350C10],[@CVS350C13]^ were used as a positive control to demonstrate the quantitative correlation of FL~R/G~ increases with the amount (dilution) of β~1~AR antibodies in the assay (*Figure [1](#CVS350F1){ref-type="fig"}C*, closed squares). The specificity cut-off for β~1~AR-related FL~R/G~ increases (*Figure [1](#CVS350F1){ref-type="fig"}C*, dashed vertical *line*) was defined by the IgG dilution at and above which commercial IgG preparations used as a bona fide β~1~AR antibody-negative control (*Figure [1](#CVS350F1){ref-type="fig"}C*, open squares) resulted in FL~R/G~ values within the background. It was determined at serum-equivalent dilutions of ≥1:500 (26.8 mg IgG/L). Consistent with this cut-off, IgG signals at cell surfaces observed upon staining at 1:500 dilution (*Figure [2](#CVS350F2){ref-type="fig"}A*, left) were absent in cells not overexpressing β~1~AR (*Figure [2](#CVS350F2){ref-type="fig"}A*, right) or overexpressing C-terminally green fluorescence protein (GFP)-fused human EGF receptors (*Figure [2](#CVS350F2){ref-type="fig"}B,* middle) or stained with second antibody alone (*Figures [1](#CVS350F1){ref-type="fig"}A* and *B*, *[2](#CVS350F2){ref-type="fig"}B*, left) or pretreated with a molar excess of peptide corresponding to the second extracellular loop of the β~1~AR (*Figure [2](#CVS350F2){ref-type="fig"}B*, right). In conclusion, FL~R/G~ increases observed at IgG dilutions of 1:500--2000 were taken to indicate β~1~AR autoantibody levels scored +, ++, and +++, respectively (*Figure [1](#CVS350F1){ref-type="fig"}C*, arrows). Figure 1Colocalization of IgG with native YFP-fused β~1~AR on the surface of human cells. (*A*) Colocalization (bottom) of β~1~AR- (top) and IgG-associated fluorescence (middle) on native cells incubated with IgG (26.8 mg/L) from a DCM patient (right), secondary antibody alone (middle) or rabbit β~1~AR-IgG (*left*); visualization at 630-fold magnification, size bar (30 μm) at top left applies to all panels. (*B*) Serial dilution of patient IgG (top) or rabbit β~1~AR-IgG (bottom) starting with 134 mg IgG/L (equivalent to 1:100 dilution of normal serum); green and red images show receptor- and IgG-associated fluorescence, respectively, at 200-fold magnification. Size bar (30 μm) at top left applies to all panels. (*C*) Cells stained with serial IgG dilutions and imaged as in (*B*); the ratio of emission intensities of red (bound IgG) and green (β~1~AR abundance) fluorescence intensities (FL~R/G~) is normalized to FL~R/G~ background with second antibody alone. FL~R/G~ increases above background (mean values from 10 fields of vision, SEM \<20% not shown) are plotted over dilution of IgG from a DCM patient (filled circle), a healthy volunteer (open circle), a commercial human-IgG preparation (open square) or rabbit antibodies against the second extracelluar loop of the human β~1~AR^13^ (filled square). Horizontal dashed line: confidence limit of FL~R/G~ background scatter (determined in 10 independent cell preparations, 30 fields of vision each). Vertical dashed line: specificity cut-off. (*D*) Scoring of β~1~AR autoantibody positivity \[criteria at the top of (*C*)\]; means of triplicate determinations of individual IgGs done on different days with different cell preparations; SEM was less than one dilution step; Bracket: *U* test. Figure 2Specificity of IgG-β~1~ARs colocalization at specificity cut-off. (*A*) β~1~AR- (top) and IgG-associated fluorescence (bottom) in wild-type cells (right) and cells expressing YFP-fused human β~1~ARs (left) or GFP-fused human EGF receptors (middle), all stained with patient IgG at 1:500 dilution (26.8 mg/L). Images obtained at 400-fold magnification, size bar of 30 μm at top left applies to all panels. (*B*) β~1~AR- (top) and IgG-associated fluorescence (bottom) in cells expressing YFP-fused human β~1~ARs and stained with secondary antibody alone (left) or human autoimmune IgG (26.8 mg/L) pre-absorbed with a 1000-fold molar excess of peptide analogues of the first (middle) or the second (right) extracellular loop of the human β~1~AR. Images obtained at 630-fold magnification. Size bar of 30 μm at top left applies to all panels.

2.4. Determination of changes in β~1~AR conformation by FRET {#s2d}
------------------------------------------------------------

Cells expressing the YFP/CFP-fused β~1~AR FRET reporter or co-expressing β~1~ARs, each bearing just one component of the fluorescent donor/acceptor pair, were cultured under an LSM 510 Meta inverted confocal microscope equipped with a 63x/1.3 DIC oil immersion objective and placed inside an XL-incubator (Carl Zeiss, Jena, Germany). The donor CFP was excited at 458 nm and fluorescent emission was recorded using the Meta detector. CFP and YFP emission spectra were separated by emission fingerprinting and corrected for bleaching during image acquisition. FRET efficiency was expressed as an emission intensity ratio *I*~YFP~/*I*~CFP~. The mean fluorescence lifetime *τ*~m~ of the donor CFP was analysed to ascertain that decreases in *I*~YFP~/*I*~CFP~ were due to alterations in FRET and not to unrelated artefacts that alter *I*~YFP~/*I*~CFP~ but not τ~m~. For this purpose, cells were cultured under a DCS-120 Confocal Scanning FLIM system (Becker & Hickl GmbH, Berlin, Germany) mounted on an IX-71 inverted microscope equipped with a 60x (NA 1.2) water immersion objective (Olympus Deutschland GmbH, Hamburg, Germany) and placed inside a cage incubator (Okolab, Naples, Italy). CFP was excited using a 405 nm diode laser (Becker & Hickl GmbH) with a pulse repetition rate of 50 MHz. Fluorescence signals in the CFP channel (BP 460--500 nm) and the YFP channel (BP 520--550 nm) were detected using H7422P-40 photomultipliers (Hamamatsu, Herrsching, Germany) connected to two TCSPC-150 modules (Becker & Hickl GmbH). Fluorescence lifetime imaging of live cells was performed by continuous fast scanning and fitting TCSPC data by a double exponential decay function using the SPC Image software (version 2.9.1, Becker & Hickl GmbH). *τ*~m~ was calculated from the multi-exponential decay of each pixel. It was ascertained that a drop in *I*~YFP~/*I*~CFP~ and a prolongation of *τ*~m~ indicated intramolecular changes of β~1~AR conformation ([Supplementary material online, *Figures S1*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1) and [*S2*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1) and [*Table S2*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1) and [*S3*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)). Maximal decreases (Δ~max~) of *I*~YFP~/*I*~CFP~ upon stimulation of the receptor are stated as the mean of three determinations done on different days with different cell preparations each based on measurements in the plasma membranes of 10 individual cells.

2.5. Measurement of β~1~AR internalization {#s2e}
------------------------------------------

β~1~AR internalization was determined by total internal reflection fluorescence (TIRF)^[@CVS350C37]^ in cells stably expressing C-terminally YFP-fused β~1~AR. An IX-81 inverted microscope equipped with a fast CCD camera and 60× (NA 1.49) oil immersion objective (Olympus, Hamburg, Germany) was used. The illumination angle was adjusted to create an evanescent wave providing excitation in a 200 nm cytosolic slice above but not including the basal cell membrane. Following the addition of isoproterenol and/or IgG, continuous quantifications of biofluorescent receptosomes in the cell slice were monitored (typical recording see [Supplementary material online, *Movie*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)) and averaged during 1000 s using ImageJ 1.4.2Q (National Institute of Health, Bethesda, USA). The mean of 10 measurements in individual cells is stated.

2.6. cAMP measurements and ERK1/2 phosphorylation {#s2f}
-------------------------------------------------

cAMP measurements in HEK293 cells expressing YFP-fused β~1~AR used published procedures.^[@CVS350C38]^ Briefly, cells were kept in serum-free medium for 24 h, exposed to stimulators and extracted with ethanol (98%, −20°C). Phosphodiesterase inhibitors were omitted from incubations unless stated otherwise. cAMP was measured in the extracts with a commercial kit (GE Healthcare, Freiburg, Germany). The detection threshold for cAMP stimulation by isoproterenol was at 5 nmol/L ([Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)*E*), which was sufficient to demonstrate cAMP stimulation by all patient IgG studied (*Figure [4](#CVS350F4){ref-type="fig"}A*). ERK1/2 phosphorylation was analysed in HEK293 cells grown to 80% confluence, kept for 24 h in serum-free medium and then subjected to treatment with receptor ligands for 10 min at 37°C. Western blots were probed with ERK antibodies (Cell Signaling, Boston, USA) and mouse monoclonal antibodies against phospho-p42/p44 MAP kinase (Thr 202/Tyr 204).

2.7. Beating rates of human embryonic cardiomyocytes {#s2g}
----------------------------------------------------

Rates of spontaneous synchronized rhythmic cardiomyocyte contraction were monitored with the xCELLigence RTCA Cardio Instrument (Roche Diagnostics, Penzberg, Germany) as published.^[@CVS350C39]^ Human embryonic cardiomyocytes (CMC-100-110-001, cellular dynamics, WI, USA) were plated on E-plate Cardio 96 wells and grown for 5 days until the beating rate was stable. For suppression of β~2~-adrenergic chronotropic effects, cells were pretreated with 10 µM atropine (Sigma, Munich, Germany) and 1 µM ICI 118551 (Sigma, Munich, Germany) for 2 h.^[@CVS350C40]^ Cells were exposed to IgG (50 mg/L, 2 h) and then isoproterenol (10 μM) was added. IgG effects on the basal beating rate and the chronotropic isoproterenol response were derived from these recording as shown in [Supplementary material online, *Figure S6*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1) using the xCELLigence Cardio Software (Roche Diagnostics). Quantitative results were derived from triplicate determinations on different days with different cell plates and simultaneous recordings in five wells per plate subjected to the same experimental condition.

2.8. Statistics {#s2h}
---------------

Results of continuous variables are stated as mean ± SEM. GraphPad PRISM 4.0a (GraphPad Software, Inc., USA) was used for linear data regression, the exclusion of normal data distribution by the Shapiro--Wilk test, and the calculation of significances by the Mann--Whitney *U* test. *P*-values \<0.05 were considered statistically significant.

3.. Results {#s3}
===========

3.1. Receptor autoantibodies detected by colocalization with native β~1~AR are frequently present in DCM patients and healthy volunteers {#s3a}
----------------------------------------------------------------------------------------------------------------------------------------

We detected β~1~AR autoantibodies in 5 of 10 samples from DCM patients and 2 of 10 samples from healthy subjects using peptide-based ELISA ([Supplementary material online, *Figure S3*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)), which conforms to previous studies.^[@CVS350C3],[@CVS350C8],[@CVS350C28],[@CVS350C41]^ Cross-reactivity with the native β~1~AR was addressed by analysing IgG colocalization with β~1~ARs on the surface of cells stably overexpressing YFP-fused human β~1~ARs that were incubated with IgG prior to fixation (*Figure [1](#CVS350F1){ref-type="fig"}A*). β~1~AR specificity of IgG signals thus obtained on the cell surface was ascertained by their absence upon the omission of first antibody (*Figure [1](#CVS350F1){ref-type="fig"}A*), pre-adsorption with a 1000-fold molar excess of a peptide homologue of the second extracellular loop of the human β~1~AR (*Figure [2](#CVS350F2){ref-type="fig"}B*) or in cells not overexpressing the β~1~AR or overexpressing GFP-fused human EGF receptors instead (*Figure [2](#CVS350F2){ref-type="fig"}A*). IgG- β~1~AR colocalization was quantified by serial IgG dilution, resulting in a dose-dependent decline of β~1~AR-associated IgG signal (*Figure [1](#CVS350F1){ref-type="fig"}B*) and corresponding shifts of FL~R/G~ in the cell membrane (*Figure [1](#CVS350F1){ref-type="fig"}C*). FL~R/G~ increases above background were quantitatively correlated to the level (dilution) of bona fide β~1~AR antibodies^[@CVS350C4],[@CVS350C10],[@CVS350C13]^ (*Figure [1](#CVS350F1){ref-type="fig"}C*, closed squares) and not obtained upon incubation with bona fide autoantibody-negative IgG at dilutions ≥1:500 (*Figure [1](#CVS350F1){ref-type="fig"}C*, open squares). In conclusion, we used FL~R/G~ increases at 1:500--2000 dilutions for scoring levels of IgG- β~1~AR colocalization (*Figure [1](#CVS350F1){ref-type="fig"}C*). At the highest sensitivity level (+), all 10 DCM patients and 7 of 10 healthy subjects were autoantibody positive. Quantitative autoantibody scores seemed significantly (*P* \< 0.5) higher in the patients (*Figure [1](#CVS350F1){ref-type="fig"}D*). Cross-comparison with the quantitative results of peptide ELISA ([Supplementary material online, *Figure S3*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)) suggested a rough correlation of the two methods with the peptide ELISA exhibiting a lesser sensitivity. Moreover, IgG- β~1~AR colocalization was significantly diminished upon cell fixation before IgG staining ([Supplementary material online, *Figure S4*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)) suggesting β~1~AR autoantibodies bind a labile conformational epitope possibly inadequately represented by immobilized peptides. Therefore, we decided to include all IgG exhibiting β~1~AR colocalization at the highest sensitivity level (+) into functional analyses, even though a more stringent assessment of receptor-antibody positivity at the (++) level fits better to previous evaluations^[@CVS350C3],[@CVS350C8],[@CVS350C28],[@CVS350C41]^ and is probably more relevant in clinical terms.

3.2. β~1~AR-colocalizing IgG trigger conformational changes of the receptor molecule not stringently correlated to cAMP stimulation {#s3b}
-----------------------------------------------------------------------------------------------------------------------------------

An IgG impact on receptor conformation was studied in cells stably expressing β~1~ARs bearing an intramolecular FRET sensor capable of reporting the activation-associated conformational switch by a rapid decrease in the emission ratio of FRET donor and acceptor fluorophores (*I*~YFP~/*I*~CFP~, *Figure [3](#CVS350F3){ref-type="fig"}A*). All IgG exhibiting β~1~AR colocalization (including the rabbit β~1~AR antibody) also decreased *I*~YFP~/*I*~CFP~, which could be blocked by pre-incubation with a peptide homologue of the second, but not of the first extracellular loop of the β~1~AR (*Figure [3](#CVS350F3){ref-type="fig"}B*). Maximal decreases in *I*~YFP~/*I*~CFP~ (Δ~max~) triggered by patient or control IgG had similar ranges and medians. The rabbit β~1~AR antibody had a similar effect (*Figure [3](#CVS350F3){ref-type="fig"}C*). Effects of individual IgG samples on receptor conformation did not add to each other or the effect of isoproterenol. Submaximal IgG effects did not preclude subsequent, maximal effects by isoproterenol (*Figure [3](#CVS350F3){ref-type="fig"}D*). Thus, the autoantibodies seemed to trigger a similar conformational switch as isoproterenol by targeting epitopes in the second extracellular β~1~AR loop, which conforms to published results of peptide pre-adsorption.^[@CVS350C6],[@CVS350C7]^ Figure 3IgG impact on receptor conformation measured by a drop in FRET efficiency. (*A*) FRET response to 10^−5^ mol/L isoproterenol (red) or buffer (black). (*B*) FRET response to patient IgG (26.8 mg/L) without (red) or with pre-adsorption (1000-fold molar excess, 10 min, 37°C) with peptide analogues of the first (Pep 1, blue) or second (Pep 2, grey) extracellular loop of the human β~1~AR. (*C*) Comparison of FRET responses \[quantification of Δ~max~ demonstrated in (*A*)\] to individual IgG (26.8 mg/L) from DCM patients (filled circle), matched healthy volunteers (open circle), commercial human-IgG preparations (open square) and rabbit β~1~AR antibodies^13^ (filled square) by the *U* test (bracket). P7 and P10 identify corresponding IgG samples in (*B*) and (*D*). Lines show medians. (*D*) FRET responses to simultaneous incubation with two individual patient IgGs (green) or sequential incubation with IgG and then isoproterenol (blue), compared with each agent alone \[black (P7), magenta (P10), and red (Iso)\].

The rabbit antibody, all patient IgG, and most β~1~AR-colocalizing IgG from healthy volunteers increased intracellular cAMP to some extent (*Figure [4](#CVS350F4){ref-type="fig"}A*). In agreement with previous findings,^[@CVS350C3],[@CVS350C24]^ patient IgGs had a significantly higher cAMP-stimulatory efficacy, although their impact on receptor conformation was not significantly different from that of β~1~AR-colocalizing IgG from healthy volunteers or the rabbit β~1~AR antibodies (*Figure [3](#CVS350F3){ref-type="fig"}C*). To address this discrepancy, we created a correlative matrix of cAMP stimulation and corresponding changes in receptor conformation (Δ~max~ of *I*~YFP~/*I*~CFP~ decrease) and used dose--response curves of isoproterenol ([Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)*E* and *J*) to determine the 99% confidence band of receptor activation by a normal agonist (*Figure [4](#CVS350F4){ref-type="fig"}B*, dotted lines). Eight of ten patient-derived IgG samples exhibited values within or above the isoproterenol-delimited confidence band (*Figure [4](#CVS350F4){ref-type="fig"}B*, closed circles), suggesting that they were as good as, or even superior to, isoproterenol in inducing receptor conformations coupled to cAMP. In contrast, six of seven β~1~AR-colocalizing IgG from healthy volunteers and the rabbit antibody were below the isoproterenol-delimited confidence band (*Figure [4](#CVS350F4){ref-type="fig"}B*, open circles and closed square, respectively), suggesting that they induced receptor conformations not or inefficiently coupled to cAMP. Figure 4cAMP stimulation by IgG and corresponding changes in β~1~AR conformation. (*A*) Fold increments of cAMP over basal levels in cells overexpressing human β~1~ARs in response to IgG (26.8 mg/L, 20 min, 37°C) from DCM patients (filled circle), matched healthy volunteers (open circle), commercial human-IgG preparations (open square) and rabbit β~1~AR antibodies (filled square). Lines show medians, symbols shown means (*n* = 6, SEM \<10% not shown). Bracket: *U* test. (*B*) Correlation of cAMP and FRET responses to IgG from DCM patients (filled circle), healthy volunteers (open circle), and rabbit β~1~AR antibodies (filled square) (mean, *n* = 3, SEM \<10% not shown), compared with responses to isoproterenol (5 × 10^--11^ -- 5 × 10^−4^ mol/L, for each concentration mean ± SEM, *n* = 3) (filled diamond). Solid and dashed lines: linear regression and 99% confidence band of the isoproterenol data. P4, P10, and H5: index samples for comparison with *Figures [5](#CVS350F5){ref-type="fig"}* and *[6](#CVS350F6){ref-type="fig"}*.

3.3. Inhibition of agonist triggered β~1~AR internalization by autoantibodies {#s3c}
-----------------------------------------------------------------------------

In the steady state of isoproterenol saturation, 20% of the biofluorescent β~1~ARs were relocated to cytosolic endosomes (*Figure [6](#CVS350F6){ref-type="fig"}A*, top, right), indicative of receptor endocytosis^[@CVS350C42]^ and recycling to the cell surface.^[@CVS350C37]^ cAMP-stimulatory receptor autoantibodies failed to induce receptor internalization (*Figure [5](#CVS350F5){ref-type="fig"}A*, bottom, left), and moreover, attenuated receptor internalization inducible by subsequent exposure to isoproterenol (*Figure [5](#CVS350F5){ref-type="fig"}A*, bottom, right) despite the overruling isoproterenol effect on receptor conformation (*Figure [3](#CVS350F3){ref-type="fig"}D*). This observation suggests that autoantibodies inhibited receptor internalization. Given the low-internalization rate of the β~1~AR,^[@CVS350C43]^ this effect could not be quantified by cell fractionation. Instead, we used TIRF^[@CVS350C37]^ to monitor the appearance of biofluorescent β~1~AR receptosomes in a 200 nm cytosolic section immediately above the basal membrane. Such receptosomes started to appear 1--2 min after isoproterenol exposure and increased in density over time ([Supplementary material online, *Movie*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)). IgG pre-incubation significantly delayed onset and decreased rates of agonist-induced receptosome trafficking (*Figure [5](#CVS350F5){ref-type="fig"}B*). Going by the mean rate of receptosome appearance during the first 17 min of agonist exposure, receptor internalization was significantly more extensively and frequently reduced by patient-derived IgG samples than by β~1~AR-colocalizing IgG from healthy volunteers, whereas commercial IgG preparations and rabbit β~1~AR antibodies had no effect on internalization (*Figure [5](#CVS350F5){ref-type="fig"}C).* The inhibitory effect was abolished by pre-adsorption with a peptide analogue of the second (but not the first) extracellular loop of the human β~1~AR (*Figure [5](#CVS350F5){ref-type="fig"}D*), suggesting that it is triggered by IgG interactions with the same receptor domain as cAMP stimulation. However, it seems unlikely that the same epitopes are involved, because the two effects were not correlated between individual IgGs (*Figure [5](#CVS350F5){ref-type="fig"}E*). Figure 5IgG inhibition of agonist-induced receptor internalization. (*A*) Confocal images (630-fold magnification, size bar of 30 μm at bottom right applies to all panels) of cells expressing YFP-fused human β~1~ARs before (top, left) or after (top, right) exposure to isoproterenol (10^−5^ mol/L, 37°C, 30 min) or after pre-incubation with autoimmune IgG (26.8 mg/L, 20 min, 37°C) (bottom, left) and subsequent isoproterenol exposure (bottom, right). (*B*) Internalized biofluorescent receptosomes quantified by TIRF following isoproterenol exposure (10^−5^ mol/L) without (blue) or with (red) IgG pre-incubation as in (*A*). (*C*) Impacts of IgG pre-incubation \[as in (*A*)\] on mean receptosome frequency averaged over 16.7 min of isoproterenol exposure. Bracket: *U* test. Dashed lines: 98% confidence band of the receptosome rate without IgG pre-incubation (*n* = 5). (*D*) Decrease of the isoproterenol-induced receptosome rate \[mean ± SEM determined as in (*C*)\] after IgG pre-incubation \[as in (*A*)\] with and without pre-absorption (1000-fold molar excess, 10 min, 37°C) with peptide analogues of first or second extracellular receptor loops (Pep 1 and 2, respectively). (*E*) IgG efficacies to stimulate cAMP and decrease agonist-triggered receptor internalization. H5, P4, and P10: index samples for comparison with *Figures [4](#CVS350F4){ref-type="fig"}* and *[6](#CVS350F6){ref-type="fig"}*. Dashed lines as in (*C*).

3.4. Modulation of agonist stimulated cAMP production and cardiomyocyte stimulation by β~1~AR autoantibodies {#s3d}
------------------------------------------------------------------------------------------------------------

The correlative matrices shown in *Figure [4](#CVS350F4){ref-type="fig"}B* and *[5](#CVS350F5){ref-type="fig"}E* suggest that different types of β~1~AR autoantibodies can be distinguished: (i) IgG (here mostly found in healthy individuals) that induce inactive receptor conformation (indexed 'H5'); (ii) IgG (here mostly found in patients) that induce active receptor conformations (indexed 'P10'); (iii) IgG (here mostly found in patients) that strongly attenuate receptor internalization (indexed 'P4'). These three IgG types were analysed with respect to their impact on isoproterenol-stimulated cAMP production. Two settings were tested: (i) IgG pre-incubation (20 min) followed by isoproterenol stimulation (*Figure [6](#CVS350F6){ref-type="fig"}A* left) and (ii) isoproterenol stimulation followed after 20 min by the addition of IgG (*Figure [6](#CVS350F6){ref-type="fig"}A* right). cAMP-time courses upon exposure to isoproterenol alone (*red symbols*) were consistent with initial stimulation followed by desensitization. They were not significantly changed by the addition of any of the above types of β~1~AR autoantibodies subsequent to isoproterenol (*Figure [6](#CVS350F6){ref-type="fig"}A* right), which conforms to the data in *Figure [3](#CVS350F3){ref-type="fig"}D* and indicates that isoproterenol overrules subsequent IgG effects on the receptor*.* However, pre-incubation of unliganded β~1~AR with autoantibodies notably affected subsequent stimulation by isoproterenol. Moreover, the three types of β~1~AR autoantibodies had different effects in this setting (*Figure [6](#CVS350F6){ref-type="fig"}A*, left): IgG-inducing inactive receptor conformations had no significant effect on the cAMP response to isoproterenol, whereas IgG-inducing active receptor conformations augmented the initial cAMP response to isoproterenol. Interestingly, β~1~AR-stimulating IgG that, in addition, strongly attenuated receptor internalization had the opposite effect; it decreased the initial cAMP response. Figure 6Modulation of cAMP stimulation and cardiomyocyte beating rate by IgG. (*A*) cAMP-time courses in HEK293 cells overexpressing human β~1~AR upon exposure to isoproterenol (10^−6^ mol/L). Left: IgG pre-incubation (50 mg/L, 20 min, 37°C). Right: IgG addition 20 min after isoproterenol. Red symbols in left and right: cAMP-time courses without IgG. Means ± SEM of triplicate determinations (for isoproterenol alone) or independent measurements with three independent IgG samples with similar properties. (*B* and *C*) IgG effects on basal beating rates (*B*) and chronotropic isoproterenol responses (*C*) of human embryonic cardiomyocytes subjected to sequential exposure to IgG (50 mg/L) and isoproterenol (10 μM). Data derived from continuous recordings, as shown in [Supplementary material online, *Figure S6*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1). Mean ± SEM of measurements with three independent IgG samples with similar properties. P4, P10, H5: indexes referring IgG properties to corresponding data points in *Figures [4](#CVS350F4){ref-type="fig"}* and *[5](#CVS350F5){ref-type="fig"}*.

The pathophysiological relevance of these divergent IgG effects was corroborated in human embryonic cardiomyocytes, using real-time impedance monitoring of the spontaneous beating rate as a readout of chronotropic effects^[@CVS350C39]^ and restricting the responsiveness of the model to β~1~AR-mediated regulation.^[@CVS350C40]^ As expected, patient-derived IgG capable of β~1~AR-mediated cAMP stimulation (indexed 'P10' and P4') significantly stimulated the basal beating rate of the cardiomyocytes, whereas IgG from healthy individuals inducing inactive receptor conformations (indexed 'H5') had no significant effect (*Figure [6](#CVS350F6){ref-type="fig"}B*). Most notably, the divergent effect of the two types of β~1~AR-stimulating IgG on isoproterenol stimulation of cAMP (*Figure [6](#CVS350F6){ref-type="fig"}A*, left) was faithfully reflected by their modulatory effect on cardiomyocyte stimulation: pre-incubation with stimulating IgG increased or decreased a subsequent chronotropic isoproterenol response depending on whether the autoantibodies in addition inhibited β~1~AR internalization (indexed 'P4') or not (indexed 'P10') (*Figure [6](#CVS350F6){ref-type="fig"}C*). This finding allows the conclusion that β~1~AR-stimulating IgG increases the basal beating rate of cardiomyocytes (which was known). In addition, they can either enhance or restrict the amplitude of the chronotropic chatecholamine response in a manner related to their inhibitory effect on receptor internalization, which is a new finding. It should be noted, however, that the enhancing effect was very minor and not significant in cardiomyocytes.

4.. Discussion {#s4}
==============

It is thought that β~1~AR autoantibodies are specifically induced in conjunction with DCM pathogenesis, because they are detected in 26--60% of DCM patients, but only 1--10% of healthy subjects.^[@CVS350C3],[@CVS350C23],[@CVS350C28],[@CVS350C41]^ Here, we detected β~1~AR autoantibodies with comparable frequency by peptide-based ELISA or high stringency scoring of IgG interactions with the native receptor. However, our data suggest that β~1~AR autoantibodies possibly occur with a much higher frequency (here in all patients and 7 of 10 healthy subjects) when a more sensitive scoring of IgG interactions with native β~1~AR is applied. We blame this discrepancy on the (fixation-) labile conformation of the autoantibody epitope, which may be inadequately represented by immobilized peptides^[@CVS350C3]^ even though soluble peptides are capable of antibody neutralization.^[@CVS350C6],[@CVS350C7]^ On the premise that IgG-β~1~AR colocalization is an adequate measure of autoantibody binding to native β~1~ARs, our data suggest that such autoantibodies could occur more frequently in patients and healthy individuals than autoantibodies interacting with immobilized peptides.^[@CVS350C3],[@CVS350C28],[@CVS350C41]^ or denatured β~1~AR.^[@CVS350C23]^ This notion underscores the previous postulate^[@CVS350C3],[@CVS350C10]^ that DCM patients are possibly distinguished not by the mere presence of β~1~AR autoantibodies but a higher level and different functional impact of their autoantibodies. However, most β~1~AR-directed IgG uncovered here in healthy individuals by high sensitivity scoring of IgG interactions with native β~1~AR had little or no effect on cAMP production or the beating rate of human embryonic cardiomyocytes suggesting that they are irrelevant in pathophysiological terms.

DCM-associated IgG stimulates cAMP production^[@CVS350C24]^ and MAP kinase signalling^[@CVS350C44]^ via the β~1~/β~2~AR, inhibits cAMP signalling via the M2-muscarinic receptor,^[@CVS350C45]^ and exerts negative inotropic effects via Fcγ receptors.^[@CVS350C46]^ These pleiotropic actions have previously been discriminated by selective antagonists and/or proteins presenting the respective binding site.^[@CVS350C6],[@CVS350C7],[@CVS350C40],[@CVS350C45],[@CVS350C47]^ In addition, we use here a purely β~1~AR regulated cell model, in which effects on MAP kinase signalling are excluded (see [Supplementary material online, *Figure S5*](http://cardiovascres.oxfordjournals.org/lookup/suppl/doi:10.1093/cvr/cvs350/-/DC1)*)* and Fcγ receptors are not present. In this restricted model, all autoantibodies colocalizing with native β~1~AR triggered conformation changes in the receptor molecule. For DCM-associated autoantibodies, such changes were mostly matched by increases in cAMP production, consistent with the induction or stabilization of active receptor conformations.^[@CVS350C10]^ Pre-incubation with most cAMP-stimulatory autoantibodies also augmented subsequent isoproterenol stimulation of intracellular cAMP suggesting that they possibly promote the agonist-coupled high-affinity state of the receptor.^[@CVS350C16]^ In contrast, most autoantibodies detected in healthy individuals induced conformation changes of the receptor molecule that were inadequately matched by increased cAMP production. This inefficiency could be due to the lower levels of these antibodies precluding a sufficient binding equilibrium or indicate stabilization of distinct alternative receptor conformations that are inactive *per se*. In any case such antibodies had no effect on the basal beating rate or chronotropic catecholamine response of human cardiomyocytes suggesting they are functionally irrelevant.

In many but not all DCM-derived IgG samples, we detected β~1~AR autoantibodies that attenuate receptor internalization triggered by isoproterenol. Our observation contradicts an earlier report on the loss of surface-binding sites in response to β~1~AR autoantibodies,^[@CVS350C48]^ but seemingly conforms to the long-standing observations that cAMP-stimulatory autoantibodies do not induce β~1~AR desensitization and inhibit desensitization by catecholamines.^[@CVS350C2]^ However, autoantibodies that significantly slowed receptor internalization also attenuated the initial cAMP response to isoproterenol, which seems more consistent with retardation of receptor regeneration following desensitization (which requires internalization^[@CVS350C42]^) than with the inhibition of desensitization itself. Interestingly, the effect of such autoantibodies on the unliganded β~1~AR entailed stimulation of basal cAMP production, suggesting an overall bimodal effect, which was clearly recapitulated in the effect of such antibodies on the basal beat rate and the chronotropic isoproterenol response of human cardiomyocytes. It should be noted that similar bimodal IgG effects were previously observed in subgroups of DCM patients.^[@CVS350C9],[@CVS350C10]^

In summary, we present here a detailed mechanistic pilot study on differential β~1~AR autoantibody effects at the level of the receptor. Our data are of limited relevance for the general population because only 10 patients and healthy individuals were analysed. However, we furnish direct evidence for the hypothesis^[@CVS350C3],[@CVS350C10]^ that β~1~AR autoantibodies trigger conformation changes in the receptor molecule. We present the new finding that β~1~AR autoantibodies can attenuate receptor internalization. We demonstrate that combinations of these properties can result in bimodal effects on receptor activity that are meaningful for basal activity and chronotropic catecholamine responses of human cardiomyocytes.
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